KR20090071668A - 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 - Google Patents

암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 Download PDF

Info

Publication number
KR20090071668A
KR20090071668A KR1020097010620A KR20097010620A KR20090071668A KR 20090071668 A KR20090071668 A KR 20090071668A KR 1020097010620 A KR1020097010620 A KR 1020097010620A KR 20097010620 A KR20097010620 A KR 20097010620A KR 20090071668 A KR20090071668 A KR 20090071668A
Authority
KR
South Korea
Prior art keywords
amino
cyclopentyl
ethyl
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097010620A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 페스투스 차알스 모패트
산제이 래티럴 패텔
스테펜 존 데이비스
케니트 윌리암 존 베이커
올리버 제임스 필립스
Original Assignee
크로마 데러퓨릭스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by 크로마 데러퓨릭스 리미티드 filed Critical 크로마 데러퓨릭스 리미티드
Publication of KR20090071668A publication Critical patent/KR20090071668A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097010620A 2006-10-25 2007-10-19 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 Withdrawn KR20090071668A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0621205.4 2006-10-25
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614.4 2007-08-10
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk

Publications (1)

Publication Number Publication Date
KR20090071668A true KR20090071668A (ko) 2009-07-01

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010620A Withdrawn KR20090071668A (ko) 2006-10-25 2007-10-19 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체

Country Status (13)

Country Link
US (1) US20100216802A1 (cg-RX-API-DMAC10.html)
EP (1) EP2079743B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010507639A (cg-RX-API-DMAC10.html)
KR (1) KR20090071668A (cg-RX-API-DMAC10.html)
AT (1) ATE542820T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007310604B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718120A2 (cg-RX-API-DMAC10.html)
CA (1) CA2665736A1 (cg-RX-API-DMAC10.html)
EA (1) EA200900593A1 (cg-RX-API-DMAC10.html)
IL (1) IL198082A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009004244A (cg-RX-API-DMAC10.html)
NZ (1) NZ577153A (cg-RX-API-DMAC10.html)
WO (1) WO2008050096A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111325A1 (ko) * 2018-11-28 2020-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668070A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US8129387B2 (en) 2006-12-14 2012-03-06 Vertex Pharmaceuticals Incorporated Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
EP2318412B1 (en) * 2008-06-23 2013-08-14 Vertex Pharmceuticals Incorporated Protein kinase inhibitors
CA2728729C (en) 2008-06-23 2016-09-27 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
KR20120081119A (ko) * 2009-09-04 2012-07-18 잘리커스 파마슈티컬즈 리미티드 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
KR20160111520A (ko) * 2014-01-31 2016-09-26 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111325A1 (ko) * 2018-11-28 2020-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
NZ577153A (en) 2012-02-24
AU2007310604A1 (en) 2008-05-02
CA2665736A1 (en) 2008-05-02
IL198082A0 (en) 2009-12-24
EP2079743A1 (en) 2009-07-22
BRPI0718120A2 (pt) 2013-11-12
JP2010507639A (ja) 2010-03-11
MX2009004244A (es) 2009-05-14
US20100216802A1 (en) 2010-08-26
AU2007310604B2 (en) 2012-02-02
WO2008050096A1 (en) 2008-05-02
ATE542820T1 (de) 2012-02-15
EA200900593A1 (ru) 2010-06-30
EP2079743B1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
EP2079743B1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
US20220370416A1 (en) Compounds and methods for targeted degradation of kras
JP7286539B2 (ja) タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法
CN101273030B (zh) 丙型肝炎病毒的大环抑制剂
US9428464B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN106061976B (zh) 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US9603889B2 (en) IAP antagonists
WO2023025116A1 (zh) 杂环类衍生物、其制备方法及其医药上的用途
US20230002396A1 (en) Therapeutic compounds
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
US20110190306A1 (en) Inhibitors of PLK
HK1211579A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
KR20130113950A (ko) Ｍｔｏｒ 선택적 키나아제 억제제
US10329324B2 (en) Indoline compounds as granzyme B inhibitors
CN102395584A (zh) 用于代谢疾病治疗的化合物
CN116783183B (zh) 用于治疗贫血和癌症的vhl抑制剂
CN111434662A (zh) 卤代烯丙基胺类化合物及其应用
WO2025218831A2 (zh) 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用
CN101541800A (zh) 用于治疗癌症的作为plk抑制剂的蝶啶衍生物
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
CN113767102A (zh) 具有抗乙型肝炎病毒(hbv)活性的新的苯基和吡啶基脲类化合物
TWI652265B (zh) 氮雜吲哚衍生物
CN116917279A (zh) Btk抑制剂
CN117186097A (zh) 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid